scispace - formally typeset
X

Xin Li

Publications -  9
Citations -  456

Xin Li is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 2 publications receiving 409 citations.

Papers
More filters
Journal ArticleDOI

CD19 or CD20 CAR T-cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with CNS Lymphoma.

TL;DR: The results of this study suggest that CD19 or CD20 CAR T-cells are effective against central nervous system (CNS) lymphoma.
Journal ArticleDOI

Deputy Editor-in-Chief

TL;DR: In this paper, the authors present a bidder list for the Journal of Experimental Biology (JEB) which includes the following authors: Stephen C. Jeb et al. (The Company of Biologists Limited Bidder Building Station Road Histon Cambridge CB24 9LF, UK Tel: +44 1223 632871 Fax:+44 12 23 632873 jeb@biologists.com Editorial Advisory Board
Journal ArticleDOI

The Threat of Carbapenem-Resistant Gram-Negative Bacteria in Patients with Hematological Malignancies: Unignorable Respiratory Non-Fermentative Bacteria-Derived Bloodstream Infections

Abstract: Background Carbapenem-resistant Gram-negative bacteria (CRGNB) bloodstream infection (BSI) pose a significant threat to the prognosis of hematologic malignancies (HM) patients. Understanding the distribution of pathogenic bacteria, changes in carbapenem-resistant trends, risk factors for CRGNB infections, and exploring the early detection measures can help reduce mortality. Methods We conducted a multicenter retrospective study of Gram-negative bacteria (GNB) BSI in patients with HM in three university-affiliated hospitals in Hunan Province, China, from January 2010 to December 2020. Demographic and clinical data were collected from the hospital electronic medical records system. Results CRGNB caused 138 (15.3%) of 902 GNB BSI. The detection rate of CRGNB increased from 6.4% in 2010–2012 to 35.4% in 2019–2020. The 7-day mortality rate was significantly higher in patients with CRGNB BSI than in patients with carbapenem-susceptible Gram-negative bacteria (CSGNB) BSI [31.9% (44/138) vs 9.7% (74/764), P < 0.001], and the mortality rate in patients with carbapenem-resistant non-fermenting bacteria (CRNFB) bloodstream infections was generally higher than that of carbapenem-resistant Enterobacteriaceae (CRE). Urinary catheter (OR, 2.814; CI=1.395–5.680; P=0.004) and prior exposure to carbapenem (OR, 4.372; CI=2.881–6.635; P<0.001) were independent risk factors for CRGNB BSI. Analysis of co-infections showed that 50%–85% of patients with CRGNB BSI had pulmonary infections, sputum culture results suggested that sputum culture positivity rate was as high as 57.1%–66.7% in patients with carbapenem-resistant Acinetobacter baumannii (CRAB) and Stenotrophomonas maltophilia BSI, and the results of antimicrobial susceptibility testing of sputum cultures were consistent with the blood cultures. Conclusion Carbapenem resistance has dramatically increased in HM patients with GNB BSI in recent years and is associated with a worse outcome, especially for non-fermenting bacteria. In high-risk patients, early screening of the respiratory tract specimens may help to detect CRNFB colonization and protect patients from breakthrough BSI.